4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Hydrogen‐deuterium exchange mass spectrometry highlights conformational changes induced by factor XI activation and binding of factor IX to factor XIa

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Factor XI ( FXI) is a zymogen in the coagulation pathway that, once activated, promotes haemostasis by activating factor IX ( FIX). Substitution studies using apple domains of the homologous protein prekallikrein have identified that FIX binds to the apple 3 domain of FXI. However, the molecular changes upon activation of FXI or binding of FIX to FXIa have remained largely unresolved.

          Objectives

          This study aimed to gain more insight in the FXI activation mechanism by identifying the molecular differences between FXI and FXIa, and in the conformational changes in FXIa induced by binding of FIX.

          Methods

          Hydrogen‐deuterium exchange mass spectrometry was performed on FXI, FXIa, and FXIa in complex with FIX.

          Results

          Both activation and binding to FIX induced conformational changes at the interface between the catalytic domain and the apple domains of FXI(a)—more specifically at the loops connecting the apple domains. Moreover, introduction of FIX uniquely induced a reduction of deuterium uptake in the beginning of the apple 3 domain.

          Conclusions

          We propose that the conformational changes of the catalytic domain upon activation increase the accessibility to the apple 3 domain to enable FIX binding. Moreover, our HDX MS results support the location of the proposed FIX binding site at the beginning of the apple 3 domain and suggest a mediating role in FIX binding for both loops adjacent to the apple 3 domain.

          Related collections

          Most cited references23

          • Record: found
          • Abstract: found
          • Article: not found

          Hydrogen exchange mass spectrometry for studying protein structure and dynamics.

          Hydrogen/deuterium exchange (HDX) mass spectrometry (MS) has become a key technique for monitoring structural and dynamic aspects of proteins in solution. This approach relies on the fact that exposure of a protein to D(2)O induces rapid amide H → D exchange in disordered regions that lack stable hydrogen-bonding. Tightly folded elements are much more protected from HDX, resulting in slow isotope exchange that is mediated by the structural dynamics ("breathing motions") of the protein. MS-based peptide mapping is a well established technique for measuring the mass shifts of individual protein segments. This tutorial review briefly discusses basic fundamentals of HDX/MS, before highlighting a number of recent developments and applications. Gas phase fragmentation strategies represent a promising alternative to the traditional proteolysis-based approach, but experimentalists have to be aware of scrambling phenomena that can be encountered under certain conditions. Electron-based dissociation methods provide a solution to this problem. We also discuss recent advances that facilitate the applicability of HDX/MS to membrane proteins, and to the characterization of short-lived protein folding intermediates. It is hoped that this review will provide a starting point for novices, as well as a useful reference for practitioners, who require an overview of some recent trends in HDX/MS.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            High levels of coagulation factor XI as a risk factor for venous thrombosis.

            Factor XI, a component of the intrinsic pathway of coagulation, contributes to the generation of thrombin, which is involved in both the formation of fibrin and protection against fibrinolysis. A deficiency of factor XI is associated with bleeding, but a role of high factor XI levels in thrombosis has not been investigated. We determined factor XI antigen levels in the patients enrolled in the Leiden Thrombophilia Study, a large population-based, case-control study (with a total of 474 patients and 474 controls) designed to estimate the contributions of genetic and acquired factors to the risk of deep venous thrombosis. Odds ratios were calculated as a measure of relative risk. The age- and sex-adjusted odds ratio for deep venous thrombosis in subjects who had factor XI levels above the 90th percentile, as compared with those who had factor XI levels at or below that value, was 2.2 (95 percent confidence interval, 1.5 to 3.2). There was a dose-response relation between the factor XI level and the risk of venous thrombosis. Adjustment of the odds ratios for other risk factors such as oral-contraceptive use, homocysteine, fibrinogen, factor VIII, female sex, and older age did not alter the result. Also, when we excluded subjects who had known genetic risk factors for thrombosis (e.g., protein C or S deficiency, antithrombin deficiency, the factor V Leiden mutation, or the prothrombin G20210A mutation), the odds ratio remained the same, indicating that the risk of venous thrombosis associated with elevated levels of factor XI was not the result of one of the known risk factors for thrombosis. High levels of factor XI are a risk factor for deep venous thrombosis, with a doubling of the risk at levels that are present in 10 percent of the population.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Structure and function of factor XI.

              Factor XI (FXI) is the zymogen of an enzyme (FXIa) that contributes to hemostasis by activating factor IX. Although bleeding associated with FXI deficiency is relatively mild, there has been resurgence of interest in FXI because of studies indicating it makes contributions to thrombosis and other processes associated with dysregulated coagulation. FXI is an unusual dimeric protease, with structural features that distinguish it from vitamin K-dependent coagulation proteases. The recent availability of crystal structures for zymogen FXI and the FXIa catalytic domain have enhanced our understanding of structure-function relationships for this molecule. FXI contains 4 "apple domains" that form a disk structure with extensive interfaces at the base of the catalytic domain. The characterization of the apple disk structure, and its relationship to the catalytic domain, have provided new insight into the mechanism of FXI activation, the interaction of FXIa with the substrate factor IX, and the binding of FXI to platelets. Analyses of missense mutations associated with FXI deficiency have provided additional clues to localization of ligand-binding sites on the protein surface. Together, these data will facilitate efforts to understand the physiology and pathology of this unusual protease, and development of therapeutics to treat thrombotic disorders.
                Bookmark

                Author and article information

                Contributors
                j.meijers@sanquin.nl
                Journal
                J Thromb Haemost
                J. Thromb. Haemost
                10.1111/(ISSN)1538-7836
                JTH
                Journal of Thrombosis and Haemostasis
                John Wiley and Sons Inc. (Hoboken )
                1538-7933
                1538-7836
                07 October 2019
                December 2019
                : 17
                : 12 ( doiID: 10.1111/jth.v17.12 )
                : 2047-2055
                Affiliations
                [ 1 ] Department of Molecular and Cellular Hemostasis Sanquin Research Amsterdam The Netherlands
                [ 2 ] Department of Pharmaceutics Utrecht Institute for Pharmaceutical Sciences (UIPS) Utrecht University Utrecht The Netherlands
                [ 3 ] Department of Experimental Vascular Medicine Amsterdam UMC University of Amsterdam Amsterdam The Netherlands
                Author notes
                [*] [* ] Correspondence

                Joost C. M. Meijers, Department of Molecular and Cellular Hemostasis, Sanquin Research, Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands.

                Email: j.meijers@ 123456sanquin.nl

                Author information
                https://orcid.org/0000-0002-0744-5569
                https://orcid.org/0000-0002-5447-7838
                https://orcid.org/0000-0002-4198-6780
                Article
                JTH14632
                10.1111/jth.14632
                6916417
                31519061
                5483f2ee-8ced-411a-9aab-13a7283d8e88
                © 2019 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 03 July 2019
                : 06 August 2019
                : 19 August 2019
                Page count
                Figures: 4, Tables: 0, Pages: 8, Words: 5488
                Funding
                Funded by: Landsteiner Foundation for Blood Transfusion Research , open-funder-registry 10.13039/100009425;
                Award ID: 1702
                Funded by: Ministerie van Volksgezondheid, Welzijn en Sport , open-funder-registry 10.13039/501100002999;
                Award ID: PPOP‐14‐01
                Categories
                Original Article
                HAEMOSTASIS
                Original Articles
                Custom metadata
                2.0
                December 2019
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.7.3 mode:remove_FC converted:17.12.2019

                Hematology
                factor ix,factor xi,factor xia,hemostasis,mass spectrometry
                Hematology
                factor ix, factor xi, factor xia, hemostasis, mass spectrometry

                Comments

                Comment on this article